Therapeutic effects were sustained off treatment, with persistent reduction in HbA1c and improvement in beta-cell function 3 months after last dose, suggesting disease-modifying potential of ...

Type 1 diabetes is an autoimmune disease characterized by progressive loss of pancreatic beta cells. Golimumab is a human monoclonal antibody specific for tumor necrosis factor α that has already been ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio PHOENIX — An SGLT2 inhibitor recently ...

An international meta-analysis including nearly 18,000 patients from five clinical trials was coordinated by the CNIC in collaboration with institutions in four other countries ...

A major analysis led by the Centro Nacional de Investigaciones Cardiovasculares (CNIC), in collaboration with international ...

REDWOOD CITY, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of ...

-- Protein expression in muscle was sustained for two years following treatment in the low dose cohort, with mean beta-sarcoglycan expression of 54% at 24 months, compared to 36% at Day 60, as ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A single 14-day course of the monoclonal antibody ...